Medtronic plc (ETR:2M6)
Germany · Delayed Price · Currency is EUR | Market Cap | 81.32B -18.3% |
| Revenue (ttm) | 30.18B +6.9% |
| Net Income | 3.92B +8.3% |
| EPS | 3.04 +9.5% |
| Shares Out | n/a |
| PE Ratio | 20.73 |
| Forward PE | 12.62 |
| Dividend | 2.43 (3.78%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | 3,261 |
| Open | 64.52 |
| Previous Close | 63.66 |
| Day's Range | 63.24 - 67.62 |
| 52-Week Range | 62.86 - 91.50 |
| Beta | 0.63 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 3, 2026 |
About Medtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair produc... [Read more]
Financial Performance
In fiscal year 2026, Medtronic's revenue was $36.36 billion, an increase of 8.43% compared to the previous year's $33.54 billion. Earnings were $4.80 billion, an increase of 2.98%.
Financial numbers in USD Financial StatementsNews
Medtronic announces investments in two intracardiac echocardiography companies
Medtronic (MDT) announced strategic investments in two privately held companies focused on the development of intracardiac echocardiography, or ICE, catheter technologies. ICE catheters provide real-t...
Medtronic Earnings Call Transcript: Q4 2026
Q4 and FY26 delivered strong revenue and EPS growth, with robust performance across cardiovascular, neuroscience, and medical-surgical segments. FY27 guidance calls for 6.75%-7.25% organic revenue growth and $5.90-$6.00 EPS, with continued investment in innovation and M&A.
Medtronic Earnings release: Q4 2026
Medtronic released its Q4 2026 earnings on June 3, 2026, summarizing the period's financial results.
Medtronic Slides: Q4 2026
Medtronic has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on June 3, 2026.
Medtronic submits 510(k) filings to expand Hugo robotic-assisted surgery system
Medtronic (MDT) announced significant milestones to unlock expanded indications for the Hugo robotic-assisted surgery system in the United States and to shape the future of surgery. General surgery in...
Medtronic Stock Rises on Earnings. Wall Street Looks Past a Soft Outlook.
The medical device maker posts fiscal fourth-quarter earnings and revenue that narrowly beat analysts' estimates.
Medtronic Posts Higher Profit, Sales
Medtronic said its profit and sales rose during its fiscal fourth quarter, reflecting steps the company has taken to improve business performance and drive growth.
Medtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United States
Company also announces 510(k) pending for LigaSure™ RAS Maryland instrument on the Hugo RAS system, and 510(k) clearance for ProGrip™ Advanced self-gripping polypropylene mesh for use in robotic-assis...
Mizuho cuts Medtronic target, sees recent selloff as overdone
Mizuho analyst Anthony Petrone lowered the firm’s price target on Medtronic (MDT) to $100 from $120 and keeps an Outperform rating on the shares. Medtronic is trading below its 13-times…
Medtronic reports Q4 EPS $1.55, consensus $1.55
Reports Q4 revenue $9.81B, consensus $9.61B. “Our performance reflects the strongest annual top-line growth Medtronic (MDT) has delivered in 10 years, powered by disciplined execution across our portf...
Medtronic sees FY27 EPS $5.90-$6.00, consensus $6.06
Sees FY27 organic revenue up 6.75%-7.25%. “We are pleased to have delivered results ahead of expectations on both revenue and EPS,” said Thierry Pieton, Medtronic (MDT) chief financial officer. “As…
Medtronic increases quarterly dividend to 72c per share
The company announced that effective June 3, the Medtronic (MDT) board of directors approved an increase in Medtronic’s cash dividend for the first quarter of fiscal year 2027, raising the…
Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadens
Investments in intracardiac echocardiography (ICE) technologies highlight Medtronic's commitment to driving durable growth in the cardiac ablation business through a differentiated portfolio of techno...
Medtronic beats quarterly estimates on robust demand for heart devices
Medtronic beat Wall Street estimates for fourth-quarter revenue and adjusted profit on Wednesday, riding the wave of steady demand for its heart devices used in complex cardiac procedures.
Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years
Disciplined execution and portfolio strength position Medtronic for continued momentum into fiscal year 2027 GALWAY, Ireland, June 3, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in...
Notable companies reporting before tomorrow’s open
Notable companies reporting before tomorrow’s open, with earnings consensus, include Medtronic (MDT), consensus $1.55… Macy’s (M), consensus 30c… Ollie’s Bargain Outlet (OLLI), consensus 87c.
7 Dividend Stocks to Beat Inflation
Historically, energy stocks have performed the best when inflation spikes.
Medtronic reinstated with a Neutral at Goldman Sachs
Goldman Sachs reinstated coverage of Medtronic (MDT) with a Neutral rating and $84 price target which offers 7.5% upside potential. The shares at current levels offer a balanced risk/reward, trading…
Medtronic plans to buy SPR Therapeutics for $650 million to expand pain treatment options
Medical device maker Medtronic said on Wednesday it plans to acquire privately held SPR Therapeutics for about $650 million in cash, expanding its portfolio of treatments for chronic pain.
Medtronic announces intent to acquire SPR Therapeutics for $650M
Medtronic (MDT) announced its intent to acquire SPR Therapeutics, a privately held medical technology company and a recognized leader in temporary, percutaneous peripheral nerve stimulation, or PNS, t...
Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain
Acquisition will enhance Medtronic's Neuromodulation portfolio with temporary peripheral nerve stimulation (PNS) technology, enabling earlier intervention for chronic pain sufferers GALWAY, Ireland, M...
Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement
Payment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) evaluating Atrioventricular Interval Mod...
FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
Atrioventricular Interval Modulation (“AVIM”) Therapy Food and Drug Administration (“FDA”) Breakthrough Device Designations span the broader population of patients with uncontrolled hypertension despi...
Medtronic announces CE Mark for Stealth AXiS™ surgical system
Following recent FDA clearances, Medtronic is accelerating access to integrated planning, navigation, and robotics platform across Europe GALWAY, Ireland, April 28, 2026 /PRNewswire/ -- Medtronic, a g...